Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes

Cancer
Elias JabbourAli Taher

Abstract

Approximately 15,000 new cases of myelodysplastic syndromes (MDS) are expected in the United States each year. The mainstay for the management of myelodysplastic syndromes (MDS) is supportive therapy with red blood cell (RBC) transfusions to improve the patient's quality of life. RBC transfusions enable adequate tissue oxygenation and increase hemoglobin levels, improve fatigue, and improve the physical and intellectual activity of patients. Up to 90% of patients with MDS will receive RBC transfusions during the course of their disease, and many will become chronically dependent on transfusions to manage their anemia. These transfusions lead to an accumulation of excess iron that, in turn, can develop into a condition known as iron overload, causing clinical consequences like hypertransaminasemia and cirrhosis, dilated cardiomyopathy, and progressive dysfunction of the endocrine glands. Studies in patients with MDS have indicated that iron overload because of RBC transfusions was an independent, adverse prognostic factor for overall survival (OS) and leukemia-free survival (LFS): OS and LFS were significantly shorter in transfusion-dependent patients with MDS than in those who were not transfusion dependent. Although the Nation...Continue Reading

References

Feb 5, 1981·The New England Journal of Medicine·A I SchaferH F Bunn
Feb 1, 1994·Cardiovascular Drugs and Therapy·P Liu, N Olivieri
Aug 1, 1996·British Journal of Haematology·P D JensenJ Ellegaard
Mar 22, 1997·BMJ : British Medical Journal·D G Oscier
Dec 23, 1999·The New England Journal of Medicine·N C Andrews
Oct 24, 2001·Annals of Hematology·W Verbeek, A Ganser
Nov 13, 2001·British Journal of Haematology·J B Porter
Oct 24, 2002·Blood·Gary M BrittenhamUNKNOWN National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Workshop
Nov 26, 2002·Hematology·Peter L GreenbergNorbert Gattermann
Dec 20, 2002·Current Opinion in Oncology·Harry Paul Erba
Jan 25, 2003·British Journal of Haematology·David BowenUNKNOWN UK MDS Guidelines Group
Apr 16, 2003·British Journal of Haematology·A J G JansenD J Van Rhenen
Jun 18, 2003·Japanese Journal of Clinical Oncology·Hisamaru Hirai
Jul 1, 1965·British Journal of Haematology·L R WEINTRAUBW H CROSBY
Mar 11, 2004·British Journal of Haematology·Peter-D Jensen
Nov 25, 2004·Hematology·Alan F ListTheo M DeWitte
Feb 11, 2005·The New England Journal of Medicine·Mario Cazzola, Luca Malcovati
Feb 11, 2005·The New England Journal of Medicine·Alan ListJerome B Zeldis
Mar 29, 2005·The Oncologist·Edvardas KaminskasRichard Pazdur
Apr 23, 2005·Seminars in Hematology·E Hellström-Lindberg
Aug 5, 2005·The New England Journal of Medicine·Barbara J Bain
Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Nov 10, 2005·PharmacoEconomics·Larry D LyndBernie J O'Brien
Jan 28, 2006·Mayo Clinic Proceedings·David P Steensma, John M Bennett
Mar 30, 2007·European Journal of Haematology·Masaaki TakatokuUNKNOWN Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes

❮ Previous
Next ❯

Citations

Feb 15, 2011·Annals of Hematology·Michel DelforgeChristophe Ravoet
Jan 1, 2010·Mediterranean Journal of Hematology and Infectious Diseases·Francesco D'AlòMaria Teresa Voso
Apr 23, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Pasquale NiscolaPaolo de Fabritiis
Jun 1, 2009·Expert Review of Hematology·Lisa Chodirker, Richard A Wells
Jun 24, 2008·Expert Opinion on Pharmacotherapy·Sridhar Srinivasan, Charles A Schiffer
Jan 17, 2012·The Journal of Supportive Oncology·Mary Laudon Thomas
Oct 11, 2011·Advances in Biological Regulation·Matilde Y FolloLucio Cocco
Jun 6, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Cédric RafatMoglie Le Quintrec
Apr 24, 2008·British Journal of Haematology·André TichelliGérard Socié
Jan 9, 2010·Journal of Cellular Biochemistry·Matilde Y FolloLucio Cocco
Feb 18, 2010·Cancer·Farshid DayyaniGuillermo Garcia-Manero
Jul 3, 2015·Current Hematologic Malignancy Reports·Christopher R Cogle
Oct 13, 2012·Advances in Biological Regulation·Matilde Y FolloLucio Cocco
Nov 10, 2009·Advances in Enzyme Regulation·Lucio CoccoGeorge Weber
May 30, 2012·Clinical Journal of Oncology Nursing·Jayshree ShahSara Tinsley
Nov 29, 2014·International Journal of Hematology·Peng JinYizhou Zheng
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matilde Y FolloLucio Cocco
Nov 26, 2009·The Annals of Pharmacotherapy·Nikolaos PapadopoulosAthanasios Kikilas
Apr 2, 2010·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·R Donald Harvey, Christopher A Fausel
Apr 2, 2010·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·R Donald Harvey
Apr 2, 2010·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Christopher A Fausel
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D SchrijversUNKNOWN ESMO Guidelines Working Group
Oct 15, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DicatoM Diederich
Mar 5, 2010·Cancer Control : Journal of the Moffitt Cancer Center·Alan F List
Dec 17, 2014·Cancer Control : Journal of the Moffitt Cancer Center·Thomas WatkinsJeffrey McCullough
Oct 18, 2008·Cancer Control : Journal of the Moffitt Cancer Center·Ghulam J Mufti, Tara L Chen
Aug 4, 2021·Drugs & Aging·Rory M Shallis, Amer M Zeidan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.